Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. director Tyler Sloat filed an initial ownership report on Form 3. This filing establishes his status as a director and discloses that there are no reportable transactions or derivative holdings included in this submission.
Hinge Health, Inc. has appointed Tyler Sloat to its Board of Directors as a Class I director, effective March 16, 2026. His term runs until the company’s 2026 annual stockholders’ meeting, and he will serve as Chair of the Compensation Committee and a member of the Audit Committee.
Sloat is currently Chief Operating Officer and Chief Financial Officer of Freshworks Inc. and previously served as CFO of Zuora Inc. He will receive standard non-employee director compensation, including an initial grant of RSUs valued at $400,000 vesting over three years, annual cash retainers for his board and committee roles, and eligibility for future annual RSU awards.
Hinge Health, Inc. Executive Chairman and Co‑Founder Gabriel M.I. Mecklenburg converted 166,666 shares of Class B Common Stock into an equal number of Class A shares on March 6, 2026 at a conversion price of $0.0000 per share. He then sold all 166,666 Class A shares in open‑market transactions at weighted average prices of $45.0224 and $45.6031, as part of a pre‑arranged Rule 10b5‑1 trading plan adopted on December 1, 2025. Following these transactions, he directly holds 1,843,102 shares of Class B Common Stock and has additional indirect Class B holdings through a GRAT and a family trust that are convertible into 1,092,119 and 383,592 shares of Class A Common Stock, respectively. The filing also notes 944,250 performance stock units held by Mecklenburg are excluded from these share counts.
Hinge Health, Inc. ownership update: Atomico Advisors IV, Ltd. and affiliated funds report beneficial ownership of 4,139,144 shares of Class A Common Stock, representing 5.1% of total outstanding equity based on 81,301,251 shares as of October 30, 2025.
The holding comprises (i) 3,376,865 shares held by Atomico IV L.P. (including 1,876,570 shares subject to a share collar dated December 8, 2025) and (ii) 762,279 shares held by Atomico IV (Guernsey), L.P. (including 423,430 shares subject to the same share collar).
Hinge Health, Inc. President James Pursley reported a tax-related share disposition. On March 1, 2026, he relinquished 5,127 shares of Class A Common Stock at a value of $42.76 per share. These shares were cancelled by the company to satisfy his federal and state tax withholding obligations from the vesting of restricted stock units. After this exempt tax-withholding transaction, Pursley directly owned 747,104 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a tax-related share disposition. On March 1, 2026, he relinquished 7,699 shares of Class A common stock at $42.76 per share, which were cancelled to cover federal and state tax withholding from vesting restricted stock units. After this exempt tax-withholding transaction, he beneficially owned 412,433 shares of Class A common stock.
Hinge Health, Inc. provides an AI-driven digital platform to treat and prevent musculoskeletal (MSK) pain using motion-tracking software, a proprietary Enso nerve-stimulation device, and an AI-supported care team of physical therapists, physicians, and health coaches. Programs span chronic and acute pain, surgery support, prevention, fall prevention, women’s pelvic health, and a new in-person MSK network, HingeSelect.
The company serves mainly self-insured employers, plus fully insured and Medicare Advantage populations, using over 60 health-plan and ecosystem partners. As of June 30, 2025, non‑affiliate equity market value was about $1.5 billion, and as of February 23, 2026, 55,816,216 Class A and 22,947,024 Class B shares were outstanding.
Hinge Health highlights rapid growth but a history of net losses, significant ongoing investment needs, reliance on AI, extensive healthcare and device regulation, and a dual‑class and preferred structure that concentrates voting power with founders and Series E holders.
Hinge Health, Inc. president James Pursley reported selling a total of 15,000 shares of Class A Common Stock in open-market transactions on February 23, 2026. The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025.
The shares were sold in three tranches at weighted average prices of $38.76, $39.95, and $40.46, with disclosed price ranges for each group of trades. After these sales, Pursley directly owned 752,231 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported open-market sales of a total of 14,763 shares of Class A common stock on February 23, 2026, at weighted average prices between roughly $38.40 and $40.46 per share. These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 12, 2025. After these transactions, Budge directly owned 420,132 shares of Hinge Health Class A common stock.